The FirstTake Podcast – NK Cell therapy, CAR-T in solid tumours and our early take on Q1 earnings season
Update: 2022-04-28
Description
Virginia Li digs into more promising data for NK CAR cell therapy, this time from Nkarta who share price doubled on the announcement. We listen to an extract from this week’s KOL View Live discussion between Michael Flanagan and Xianxin Hua, professor of cancer biology at the University of Pennsylvania’s Perelman School of Medicine, about the progress of CAR-T therapies as potential treatments for solid tumours. And Simon King provides some early thoughts on key trends from first quarter earnings season, including uncertainty around future COVID-19-related revenues and Big Pharma’s appetite for M&A.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
